Test Price
2,800 AED✅ Home Collection Available
KCNA2 Gene Sequencing for Early Infantile Epileptic Encephalopathy Type 32 (EIEE32) in UAE | 2800 AED | DHA-Compliant Molecular Diagnostics
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic post-test clinical guidance in result interpretation with a DHA-licensed consultant medical geneticist.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731 – most UAE payers accepted under DHA mandates.
Test Overview & Methodology
The KCNA2 Gene Sequencing (NGS) detects pathogenic variants responsible for Early Infantile Epileptic Encephalopathy Type 32 (EIEE32), a severe neonatal-onset epileptic disorder. This test provides definitive molecular diagnosis at 99.9% sensitivity using next-generation sequencing, outperforming targeted Sanger panels in speed and variant coverage.
| Feature | Our Test: KCNA2 NGS | Sanger Sequencing (Single-Gene) |
|---|---|---|
| Precision | 99.9% sensitivity for single nucleotide variants, indels, and copy number changes | ~95% sensitivity, may miss large deletions/duplications |
| Method | Full gene NGS (Next-Generation Sequencing) with bioinformatics curation | Capillary electrophoresis, limited to coding exons |
| Turnaround | 3 – 4 Weeks (guaranteed) | 4 – 6 Weeks |
| Included Support | Pre-test genetic counselling, post-test clinical interpretation | Often requires separate counselling arrangements |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I advise that a positive KCNA2 result establishes the molecular aetiology but must never be interpreted in isolation. Genetic counselling is essential to contextualise the variant, discuss recurrence risks, and coordinate multidisciplinary care including neurology and developmental paediatrics. Our telephonic guidance ensures families receive accurate, compassionate support throughout the diagnostic journey.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Safety Advisory
⛔ Critical Warning
Do not discontinue prescribed antiepileptic drugs without consulting your treating physician. Abrupt cessation may trigger life-threatening status epilepticus. Always follow the tapering schedule advised by your neurologist.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria: This genetic test is not indicated for individuals without clinical seizures or a family history suggestive of EIEE32. If the child exhibits prolonged convulsions, respiratory distress, or loss of consciousness, call 998 immediately. Do not wait for genetic test results to address acute emergencies.
Patient FAQ & Clinical Guidance
1. What is KCNA2 gene testing and who should consider it?
Direct Answer: KCNA2 gene sequencing identifies pathogenic variants causing Early Infantile Epileptic Encephalopathy Type 32, a drug-resistant neonatal epilepsy, and is indicated for infants with refractory seizures and developmental delay.
2. How is the sample collected and when will I receive results?
Direct Answer: Our team collects a small blood sample, extracted DNA, or a dried blood spot on an FTA card at your home via VIP Mobile Phlebotomy, and results are ready in 3–4 weeks with a telephonic genetic counselling session.
3. Will my insurance cover this under UAE regulations?
Direct Answer: We verify insurance eligibility directly via WhatsApp (+971 54 548 8731), and most UAE medical schemes cover medically necessary genetic testing for neurological disorders under DHA guidelines.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety follow Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is fully licensed by the Dubai Health Authority (DHA) under facility license number 1143, operating from Dubai Healthcare City.
Clinical & Logistical Metadata
| Test Name | KCNA2 Gene Sequencing (NGS) for Early Infantile Epileptic Encephalopathy Type 32 (EIEE32) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks (guaranteed) |
| Sample Type / Matrix | Peripheral whole blood, extracted DNA, or dried blood spot on FTA card – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) – full gene coverage with bioinformatics variant curation |
| ICD-10-CM Code | G40.4 |
| LOINC Code | 21656-9 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians